|
1
|
Yonehara S, Ishii A and Yonehara M: A
cell-killing monoclonal antibody (anti-Fas) to a cell surface
antigen co-downregulated with the receptor of tumor necrosis
factor. J Exp Med. 169:1747–1756. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Trauth BC, Klas C, Peters AM, et al:
Monoclonal antibody-mediated tumor regression by induction of
apoptosis. Science. 245:301–305. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Itoh N, Yonehara S, Ishii A, et al: The
polypeptide encoded by the cDNA for human cell surface antigen Fas
can mediate apoptosis. Cell. 66:233–243. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oehm A, Behrmann I, Falk W, et al:
Purification and molecular cloning of the APO-1 cell surface
antigen, a member of the tumor necrosis factor/nerve growth factor
receptor superfamily. Sequence identity with the Fas antigen. J
Biol Chem. 267:10709–10715. 1992.PubMed/NCBI
|
|
5
|
Hammam O, Mahmoud O, Zahran M, et al: The
role of fas/fas ligand system in the pathogenesis of liver
cirrhosis and hepatocellular carcinoma. Hepat Mon. 12:e61322012.
View Article : Google Scholar
|
|
6
|
El Bassiouny AE, El-Bassiouni NE, Nosseir
MM, et al: Circulating and hepatic Fas expression in HCV-induced
chronic liver disease and hepatocellular carcinoma. Medscape J Med.
10:1302008.PubMed/NCBI
|
|
7
|
Lee YB, Kyung Kim E, Park HJ, et al:
Expression of Fas and Fas ligand in primary cutaneous squamous cell
carcinoma in association with grade of tumor differentiation. Int J
Dermatol. 52:1092–1097. 2013. View Article : Google Scholar
|
|
8
|
Sjostrom-Mattson J, Von Boguslawski K,
Bengtsson NO, Mjaaland I, Salmenkivi K and Blomqvist C: The
expression of p53, bcl-2, bax, fas and fasL in the primary tumor
and lymph node metastases of breast cancer. Acta Oncol.
48:1137–1143. 2009. View Article : Google Scholar
|
|
9
|
Bebenek M, Dus D and Kozlak J: Fas
expression in primary breast cancer is related to neoplastic
infiltration of perilymphatic fat. Adv Med Sci. 53:49–53. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang D, Torres CM, Bardhan K, Zimmerman M,
McGaha TL and Liu K: Decitabine and vorinostat cooperate to
sensitize colon carcinoma cells to Fas ligand-induced apoptosis in
vitro and tumor suppression in vivo. J Immunol. 188:4441–4449.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu Y, Bae S, Kim H, et al: The anti-tumor
activity of vitamin C via the increase of Fas (CD95) and MHC I
expression on human stomach cancer cell line, SNU1. Immune Netw.
11:210–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Volkmann M, Schiff JH, Hajjar Y, et al:
Loss of CD95 expression is linked to most but not all p53 mutants
in European hepatocellular carcinoma. J Mol Med (Berl). 79:594–600.
2001. View Article : Google Scholar
|
|
13
|
Hughes MA, Harper N, Butterworth M, Cain
K, Cohen GM and MacFarlane M: Reconstitution of the death-inducing
signaling complex reveals a substrate switch that determines
CD95-mediated death or survival. Mol Cell. 35:265–279. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kober AM, Legewie S, Pforr C, et al:
Caspase-8 activity has an essential role in CD95/Fas-mediated MAPK
activation. Cell Death Dis. 2:e2122011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bajt ML, Vonderfecht SL and Jaeschke H:
Differential protection with inhibitors of caspase-8 and caspase-3
in murine models of tumor necrosis factor and Fas receptor-mediated
hepatocellular apoptosis. Toxicol Appl Pharmacol. 175:243–252.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao LJ, Zhao S, Zhao EH, et al:
Clinicopathological and prognostic significance of Ki-67, caspase-3
and p53 expression in gastric carcinomas. Oncol Lett. 6:1277–1284.
2013.PubMed/NCBI
|
|
17
|
Sun BH, Zhang J, Wang BJ, et al: Analysis
of in vivo patterns of caspase 3 gene expression in primary
hepatocellular carcinoma and its relationship to p21(WAF1)
expression and hepatic apoptosis. World J Gastroenterol. 6:356–360.
2000.
|
|
18
|
Lindahl T, Satoh MS, Poirier GG and
Klungland A: Post-translational modification of poly(ADP-ribose)
polymerase induced by DNA strand breaks. Trends Biochem Sci.
20:405–411. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bi FF, Li D and Yang Q: Hypomethylation of
ETS transcription factor binding sites and upregulation of PARP1
expression in endometrial cancer. Biomed Res Int. 2013:9462682013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu W, Kong Z, Duan X, et al: Inhibition of
PARP1 by small interfering RNA enhances docetaxel activity against
human prostate cancer PC3 cells. Biochem Biophys Res Commun.
442:127–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He W, Liu T, Shan Y, Zhu K and Li Y: PARP1
polymorphisms increase the risk of gastric cancer in a Chinese
population. Mol Diagn Ther. 16:35–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim J, Pyun JA, Cho SW, Lee K and Kwack K:
Lymph node metastasis of gastric cancer is associated with the
interaction between poly (ADP-ribose) polymerase 1 and matrix
metallopeptidase 2. DNA Cell Biol. 30:1011–1017. 2011. View Article : Google Scholar : PubMed/NCBI
|
